Status:
COMPLETED
A Phase II Study of DMP 115 to Assess Focal Liver Lesions
Lead Sponsor:
Lantheus Medical Imaging
Conditions:
Liver Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To determine the optimal dose of DMP 115 to image liver lesions and to assess whether contrast can improve the detection of focal liver lesions.
Eligibility Criteria
Inclusion
- Diagnosed with 1 but \<7 focal liver lesions
- Scheduled for liver biopsy within 30 days of study
- Scheduled for CT or MR within 30 days of study
Exclusion
- Critically ill subjects
- Subjects with right-to-left shunts
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00162058
Start Date
March 1 2004
End Date
April 1 2006
Last Update
August 18 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Glasgow, Scotland, United Kingdom